Stanford Bio-X Researchers’ “Decoy Drug” Could Someday Do Wonders For Alzheimer’s Disease

Stanford Bio-X Researchers’ “Decoy Drug” Could Someday Do Wonders For Alzheimer’s Disease
Stanford Bio-X Researchers' "Decoy Drug" Could Someday Do Wonders For Alzheimer's DiseaseA recent study revealed the mechanism to restore the capability of neurons to form new synapses, entitled, "Blocking PirB up-regulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia," which was published in Science Translational Medicine by David Bochner and Richard W. Sapp, first co-authors from the work, part of the group of Dr. Carla Shatz, from the Department of Biology and Bio-X, Stanford University, CA, U.S.A. the findings of the study suggest that the newfound capability may have the potential to be applied to clinical conditions such as stroke, forms of blindness, or Alzheimer's disease. During brain development, the neurons respond to various stimuli by forming new synapses, although this capacity decreases substantially in adults. Dr. Shatz and collaborators described previously a protein called Paired-immunoglobulin-like receptor B (PirB), a major histocompatibility complex class I (MHCI) receptor, localized in mice on the surface of neurons and immune cells. The PirB protein seems to control the time “window” for synapse formation. When
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *